Literature DB >> 23102915

The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression.

M Lucrecia Alvarez1, Johanna K Distefano.   

Abstract

Diabetic nephropathy, a progressive kidney disease that develops secondary to diabetes, is the major cause of chronic kidney disease in developed countries, and contributes significantly to increased morbidity and mortality among individuals with diabetes. Although the causes of diabetic nephropathy are not fully understood, recent studies demonstrate a role for epigenetic factors in the development of the disease. For example, non-coding RNA (ncRNA) molecules, including microRNAs (miRNAs), have been shown to be functionally important in modulating renal response to hyperglycemia and progression of diabetic nephropathy. Characterization of miRNA expression in diabetic nephropathy from studies of animal models of diabetes, and in vitro investigations using different types of kidney cells also support this role. The goal of this review, therefore, is to summarize the current state of knowledge of specific ncRNAs involved in the development of diabetic nephropathy, with a focus on the potential role of miRNAs to serve as sensitive, non-invasive biomarkers of kidney disease and progression. Non-coding RNAs are currently recognized as potentially important regulators of genes involved in processes related to the development of diabetic nephropathy, and as such, represent viable targets for both clinical diagnostic strategies and therapeutic intervention.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23102915     DOI: 10.1016/j.diabres.2012.10.010

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  51 in total

1.  Long non-coding RNA LINC00346, LINC00578, LINC00673, LINC00671, LINC00261, and SNHG9 are novel prognostic markers for pancreatic cancer.

Authors:  Baogang Zhang; Changfeng Li; Zhixia Sun
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  Cardiac hypertrophy is positively regulated by long non-coding RNA PVT1.

Authors:  Yi-Hui Yu; Zuo-Ying Hu; Ming-Hui Li; Bing Li; Zhi-Mei Wang; Shao-Liang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  Emerging roles for miRNAs in the development, diagnosis, and treatment of diabetic nephropathy.

Authors:  Johanna K DiStefano; Matthew Taila; M Lucrecia Alvarez
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

4.  RNA-seq methods for identifying differentially expressed gene in human pancreatic islet cells treated with pro-inflammatory cytokines.

Authors:  Bo Li; Chang Long Bi; Ning Lang; Yu Ze Li; Chao Xu; Ying Qi Zhang; Ai Xia Zhai; Zhi Feng Cheng
Journal:  Mol Biol Rep       Date:  2014-03-12       Impact factor: 2.316

Review 5.  Noncoding RNAs in vascular disease.

Authors:  Amy Leung; Rama Natarajan
Journal:  Curr Opin Cardiol       Date:  2014-05       Impact factor: 2.161

6.  Alterations of urinary metabolite profile in model diabetic nephropathy.

Authors:  Donald F Stec; Suwan Wang; Cody Stothers; Josh Avance; Deon Denson; Raymond Harris; Paul Voziyan
Journal:  Biochem Biophys Res Commun       Date:  2014-12-10       Impact factor: 3.575

Review 7.  Epigenetic mechanisms in diabetic complications and metabolic memory.

Authors:  Marpadga A Reddy; Erli Zhang; Rama Natarajan
Journal:  Diabetologia       Date:  2014-12-07       Impact factor: 10.122

8.  Pentraxin-3 Attenuates Renal Damage in Diabetic Nephropathy by Promoting M2 Macrophage Differentiation.

Authors:  Huaibin Sun; Jun Tian; Wanhua Xian; Tingting Xie; Xiangdong Yang
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

9.  Long Noncoding RNA-Sox2OT Knockdown Alleviates Diabetes Mellitus-Induced Retinal Ganglion Cell (RGC) injury.

Authors:  Chao-Peng Li; Shu-Hong Wang; Wen-Qi Wang; Shu-Guang Song; Xiu-Ming Liu
Journal:  Cell Mol Neurobiol       Date:  2016-05-18       Impact factor: 5.046

10.  Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.

Authors:  Naoki Nakagawa; Luke Barron; Ivan G Gomez; Bryce G Johnson; Allie M Roach; Sei Kameoka; Richard M Jack; Mark L Lupher; Sina A Gharib; Jeremy S Duffield
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.